299.00
299.00
Inclusive of all taxes
You Save: 0. Discount 0%
Product is not available
ETHAMSIG 500 TAB is a high-strength hemostatic tablet containing Ethamsylate 500 mg, formulated to control capillary bleeding in various medical conditions, including menorrhagia, epistaxis, post-surgical bleeding, and intracranial hemorrhage. Manufactured by BluepillExpress, this product is trusted globally for its anti-hemorrhagic and vascular stabilizing action, making it a reliable option for hospitals, clinics, and emergency medical care settings. BluepillExpress offers this formulation for bulk manufacturing, private labeling, and export markets across regulated and semi-regulated zones.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
ETHAMSIG 500 TAB, offered by BluepillExpress, is a high-quality, pharmaceutical-grade Ethamsylate 500 mg tablet used to manage and prevent various forms of bleeding caused by fragile blood vessels or platelet disorders. Ethamsylate is a non-hormonal, non-steroidal hemostatic agent that enhances capillary stability, improves platelet adhesion, and reduces bleeding time without affecting the coagulation cascade.
This medication plays a vital role in reducing abnormal bleeding from small vessels and is used in both emergency and preventive scenarios in gynecology, surgery, ENT, ophthalmology, and general medicine. With a rapid onset of action, ETHAMSIG 500 TAB promotes hemostasis without the risks associated with hormonal or anticoagulant therapies.
✅ Therapeutic Indications
Menorrhagia (heavy menstrual bleeding)
Post-operative bleeding (e.g., dental surgery, ENT, gynecologic procedures)
Epistaxis (nosebleeds)
Hematuria
Periventricular and intraventricular hemorrhage in neonates
Postpartum hemorrhage
Bleeding due to platelet dysfunction or capillary fragility
✅ Mechanism of Action
Ethamsylate works by:
Increasing capillary endothelial resistance, preventing rupture
Enhancing platelet aggregation and adhesion to damaged blood vessel walls
Reducing prostaglandin synthesis, which decreases bleeding
Stimulating thromboplastin formation at the injury site for faster clot formation
It does not affect coagulation time or fibrinolysis, making it safe for patients with clotting disorders or those on anticoagulants.
✅ Pharmacokinetics
Onset of Action: 1–2 hours (oral), 5–15 minutes (IV/IM)
Bioavailability: ~70–90% orally
Peak Plasma Levels: Within 4 hours
Half-life: 2–3 hours
Excretion: Renal (90% within 24 hours)
